Y-mAbs/$YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
$YMAB
Sector
Primary listing
Employees
104
Headquarters
Website
Y-mAbs Metrics
BasicAdvanced
$390M
-
-$0.49
0.56
-
Price and volume
Market cap
$390M
Beta
0.56
52-week high
$15.39
52-week low
$3.55
Average daily volume
1.6M
Financial strength
Current ratio
4
Quick ratio
3.401
Long term debt to equity
3.015
Total debt to equity
3.571
Profitability
EBITDA (TTM)
-17.766
Gross margin (TTM)
81.49%
Net profit margin (TTM)
-26.03%
Operating margin (TTM)
-25.66%
Effective tax rate (TTM)
1.74%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-8.67%
Return on equity (TTM)
-24.31%
Valuation
Price to revenue (TTM)
4.52
Price to book
4.46
Price to tangible book (TTM)
4.57
Price to free cash flow (TTM)
-21.536
Free cash flow yield (TTM)
-4.64%
Free cash flow per share (TTM)
-0.398
Growth
Revenue change (TTM)
-1.34%
Earnings per share change (TTM)
-12.02%
3-year revenue growth (CAGR)
28.92%
3-year earnings per share growth (CAGR)
-45.70%
What the Analysts think about Y-mAbs
Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.
Bulls say / Bears say
SERB Pharmaceuticals' pending acquisition of Y-mAbs for $412 million at $8.60 per share represents a 105% premium to pre-announcement prices, crystallizing substantial value for shareholders. (Fierce Pharma)
Y-mAbs reported an adjusted EPS loss of $0.07 in Q2 2025, beating analyst expectations of a $0.27 loss, highlighting improved operational efficiency despite current market pressures. (Reuters)
Wall Street analysts have put a median 12-month price target of $8.60 on Y-mAbs, suggesting only about 1% upside from recent trading levels. (Reuters)
Y-mAbs' Q2 2025 total revenue of $19.5 million is down 14% year-over-year, due to decreased DANYELZA net product sales in both U.S. and ex-U.S. markets, signaling substantial commercial challenges. (Reuters)
Management cautions that Y-mAbs may run out of available capital sooner than expected if current assumptions prove incorrect, possibly requiring more funding ahead of 2027. (Y-mAbs IR)
Y-mAbs' Radiopharmaceutical SADA PRIT platform is still in early Phase 1 trials with no revenue generated yet, so future growth rests on unproven clinical results. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Y-mAbs Financial Performance
Revenues and expenses
Y-mAbs Earnings Performance
Company profitability
Y-mAbs News
AllArticlesVideos
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
Business Wire4 weeks ago
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
Business Wire4 weeks ago
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $390M as of September 05, 2025.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of September 05, 2025.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.